title: Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.
abstract: OBJECTIVE
  To determine if the use of sitagliptin in newly treated patients with type 2 diabetes is associated with any changes in clinical outcomes.
  
  
  METHODS
  Retrospective population based cohort study.
  
  
  METHODS
  Large national commercially insured US claims and integrated laboratory database.
  
  
  METHODS
  Inception cohort of new users of oral antidiabetic drugs between 2004 and 2009 followed until death, termination of medical insurance, or December 31 2010.
  
  
  METHODS
  Composite endpoint of all cause hospital admission and all cause mortality, assessed with time varying Cox proportional hazards regression after adjustment for demographics, clinical and laboratory data, pharmacy claims data, healthcare use, and time varying propensity scores.
  
  
  RESULTS
  The cohort included 72,738 new users of oral antidiabetic drugs (8032 (11%) used sitagliptin; 7293 (91%) were taking it in combination with other agents) followed for a total of 182,409 patient years. The mean age was 52 (SD 9) years, 54% (39,573) were men, 11% (8111) had ischemic heart disease, and 9% (6378) had diabetes related complications at the time their first antidiabetic drug was prescribed. 14,215 (20%) patients met the combined endpoint. Sitagliptin users showed similar rates of all cause hospital admission or mortality to patients not using sitagliptin (adjusted hazard ratio 0.98, 95% confidence interval 0.91 to 1.06), including patients with a history of ischemic heart disease (adjusted hazard ratio 1.10, 0.94 to 1.28) and those with estimated glomerular filtration rate below 60 mL/min (1.11, 0.88 to 1.41).
  
  
  CONCLUSIONS
  Sitagliptin use was not associated with an excess risk of all cause hospital admission or death compared with other glucose lowering agents among newly treated patients with type 2 diabetes. Most patients prescribed sitagliptin in this cohort were concordant with clinical practice guidelines, in that it was used as add-on treatment.
authors.affiliation: Department of Public Health Sciences, School of Public Health, University of Alberta, Edmonton, AB, Canada T6G 2G3. deurich@ualberta.ca
authors.forename: D T
authors.initials: DT
authors.lastname: Eurich
authors.forename: S
authors.initials: S
authors.lastname: Simpson
authors.forename: A
authors.initials: A
authors.lastname: Senthilselvan
authors.forename: C V
authors.initials: CV
authors.lastname: Asche
authors.forename: J K
authors.initials: JK
authors.lastname: Sandhu-Minhas
authors.forename: F A
authors.initials: FA
authors.lastname: McAlister
mesh_terms: D057186:Comparative Effectiveness Research; D015986:Confounding Factors, Epidemiologic; D048909:Diabetes Complications / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007348:Insurance, Health / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000453:epidemiology; D017410:Practice Guidelines as Topic; D057216:Propensity Score; D016016:Proportional Hazards Models; D011719:Pyrazines / Q000494:pharmacology / Q000627:therapeutic use*; D012189:Retrospective Studies; D000068900:Sitagliptin Phosphate; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*; D014481:United States / Q000453:epidemiology
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D011719:Pyrazines; D014230:Triazoles; D000068900:Sitagliptin Phosphate